Welcome

Ophthalmology franchise strategy

Ophthalmology clinical development

Angiogenesis highlights

Q&A

Bruno Eschli, Head of Investor Relations

Nilesh Mehta, Global Franchise Head, Ophthalmology

Christopher Brittain, Vice President and Global Head of Ophthalmology Product Development

2-Year data for Susvimo in nAMD (Ph III Archway), 2-Year data for Vabysmo in DME (Ph III YOSEMITE & RHINE), Nancy Holekamp, M.D., Retina Specialist